



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Pediatrics*

Manuscript NO: 82087

Title: Vaccination coverage in children with juvenile idiopathic arthritis, inflammatory bowel diseases, and healthy peers: cross-sectional electronic survey data.

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06237902

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Russia

Manuscript submission date: 2022-12-04

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-12-05 05:06

Reviewer performed review: 2022-12-07 07:40

Review time: 2 Days and 2 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous
	Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No

SPECIFIC COMMENTS TO AUTHORS

Children with immune-mediated diseases, such as juvenile idiopathic arthritis (JIA) and inflammatory bowel disease (IBD) are susceptible to infection. But in the meantime, they often have lower vaccine coverage due to their compromised immune system, and adverse reactions such as fever were frequently reported by their parents. This paper reported the reasons for incomplete vaccinations in these groups. The results are valuable for improve the future vaccination schedule for these children. Hence, I recommend the publication of this paper after addressing the following issues. 1. In the section of Results, a fourth part is suggested to clearly show the main reasons for incomplete vaccination. 2. Please use more diagrams to intuitively show the survey data and the interactions and associations among these factors. 3. Previous reports have reported several reasons for incomplete vaccination mainly from the physicians' point of view. On the other hand, for the parents, there is an information gap. Equivocal advice on vaccination for the parents maybe means 'don't vaccinate'. Therefore, it's better to give a practical program that can be implemented at the end of the text. 4. In the Conclusion, a statement is suggested to highlight the importance of increasing immunization coverage and implementing advocacy events among special groups.



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Pediatrics*

Manuscript NO: 82087

Title: Vaccination coverage in children with juvenile idiopathic arthritis, inflammatory bowel diseases, and healthy peers: cross-sectional electronic survey data.

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03307766

Position: Editorial Board

Academic degree: MD, MSc, PhD

Professional title: Associate Professor, Director, Doctor

Reviewer's Country/Territory: Kazakhstan

Author's Country/Territory: Russia

Manuscript submission date: 2022-12-04

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-01-01 05:50

Reviewer performed review: 2023-01-01 06:50

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

INTRODUCTION - “Biologic therapy with and without immune-suppressors can reliably control inflammatory activity in many patients with immune-mediated diseases, including JIA and IBD.” The authors should add a very brief overview of the biological therapies currently used in JIA (Biologics for the Treatment of Juvenile Idiopathic Arthritis. Curr Med Chem. 2018;25(42):5860-5893. doi: 10.2174/0929867325666180522085716) and pediatric IBDs (Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Nov 29;24(12):2527-2542. doi: 10.1093/ibd/izy189) by referring to the appropriate references.

- “Infections are the most common complications associated with biologic treatment and immune-suppressors (6-8).” The authors should provide a short background information about these infectious complications supported by these references.

- “Vaccination is a well-known and effective tool, which.... of view, but studies from parental point of view are limited.” I suggest the authors shortening all this part in order to provide the essential background only with general concepts. Actually, some details and information included in this part may better fit and then be used in the discussion.

- Conversely, a



final paragraph clearly stating the general objective of the present study is missing in the introduction. METHODS - I suggest the authors to organize all this section in subsections with specific subheadings (not only the statistical part) [e.g. study design and population, ethical statement, survey, data collection, statistical analysis, others] - Moreover, this section should be expanded in my opinion. - "In the cross-sectional study we included the data from a questionnaire survey of 190 legal representatives of children, with JIA (n=81), IBD (n=51) and healthy children HC (n=58)". The information about the eligible patients' responsiveness is a result and then, should be postponed to this section. - More detailed information about the survey content is needed in the manuscript (of course, the survey could be also provided as supplementary material, as an additional resource). - It is not clear how the HCs were recruited and, in detail, this groups should be clearly defined. - The ethical statement should be added in this section, by including IRB approval date and number, and informed consent information. - The study period is not specified. - Overall, this section should be re-organized and carefully revised. RESULTS - Except for the comment expressed in the previous section, this section is well-organized overall. - However, I would suggest the authors separate the demographics information and surveys results in the table 1. I mean, I suggest one table related to demographic, clinical, and therapeutic aspects, and a different tables to summarize all the survey's results. - the numerical expression of p-values in the table(s) should be standardized and the significant values should be graphically highlighted. DISCUSSION - I suggest the authors to list and highlight the main findings emerging from the present study. - These findings should be discussed one by one in light of the available literature. - Based on the study (which is not clear at the moment), some additional discussion related to COVID19 potential impact on the survey may be appropriate. - Therefore, I think the re-review of this paper and, in detail, discussion can be completed after the additional information is provided and previous comments are



Baishideng Publishing Group

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

addressed.



RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: *World Journal of Clinical Pediatrics*

Manuscript NO: 82087

Title: Vaccination coverage in children with juvenile idiopathic arthritis, inflammatory bowel diseases, and healthy peers: cross-sectional electronic survey data.

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03307766

Position: Editorial Board

Academic degree: MD, MSc, PhD

Professional title: Associate Professor, Director, Doctor

Reviewer's Country/Territory: Kazakhstan

Author's Country/Territory: Russia

Manuscript submission date: 2022-12-04

Reviewer chosen by: Li-Li Wang

Reviewer accepted review: 2023-02-03 11:04

Reviewer performed review: 2023-02-04 01:27

Review time: 14 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The authors addressed my comments, overall. Some minor writing corrections in writing and appropriate format of all references are needed.



RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: *World Journal of Clinical Pediatrics*

Manuscript NO: 82087

Title: Vaccination coverage in children with juvenile idiopathic arthritis, inflammatory bowel diseases, and healthy peers: cross-sectional electronic survey data.

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06237902

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Russia

Manuscript submission date: 2022-12-04

Reviewer chosen by: Li-Li Wang

Reviewer accepted review: 2023-02-05 06:44

Reviewer performed review: 2023-02-06 04:06

Review time: 21 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Based on their response to the reviewers' comments and the effort the authors have been made to improve the manuscript, I believe that this manuscript is acceptable. The authors have revised the manuscript in accordance with the reviewers' comments and have properly responded to these comments raised by the reviewers.